BioVie Inc. (NASDAQ: BIVI) reported topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage Parkinson's disease, with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE